Condition: B-cell Acute Lymphoblastic Leukemia · Diffuse Large B-cell Lymphoma · Sponsor: Novartis Pharmaceuticals
This study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product. Specifically, this study will evaluate the safety of CTL019 in the patients treated within the approved label by Japan Health Authority in Part 2. Only for Part 1, in addition to safety, key efficacy of CTL019 will also be evaluated.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +41613241111 · Novartis.email@novartis.com
Novartis Pharmaceuticals · +81337978748 · Novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Hamilton, Ontario, Canada | Completed |
| Novartis Investigative Site | Ottawa, Ontario, Canada | Withdrawn |
| Novartis Investigative Site | Toronto, Ontario, Canada | Completed |
| Novartis Investigative Site | Toronto, Ontario, Canada | Completed |
| Novartis Investigative Site | Montreal, Quebec, Canada | Withdrawn |
| Novartis Investigative Site | Québec, Quebec, Canada | Withdrawn |
| Novartis Investigative Site | Nagoya, Aichi-ken, Japan | Recruiting |
| Novartis Investigative Site | Nagoya, Aichi-ken, Japan | Recruiting |
| Novartis Investigative Site | Tōon, Ehime, Japan | Recruiting |
| Novartis Investigative Site | Gifu, Gifu, Japan | Recruiting |
| Novartis Investigative Site | Sapporo, Hokkaido, Japan | Recruiting |
| Novartis Investigative Site | Sapporo, Hokkaido, Japan | Recruiting |
+ 42 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04094311